Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies: an open-label, multicentre, phase 1, dose-escalation and dose-expansion study-Reference-Cited by-同舟云学术

Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies: an open-label, multicentre, phase 1, dose-escalation and dose-expansion study

Published:2021-12 Issue:12 Volume:22 Page:1764-1776
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Fischer Matthias,Moreno Lucas,Ziegler David S,Marshall Lynley V,Zwaan C Michel,Irwin Meredith S,Casanova Michela,Sabado Constantino,Wulff Beate,Stegert Mario,Wang Luojun,Hurtado Felipe K,Branle Fabrice,Geoerger Birgit,Schulte Johannes H

Funder

Novartis Pharmaceuticals Corporation

Publisher

Elsevier BV

Subject

Oncology

Reference31 articles.

1. Anaplastic lymphoma kinase as a cancer target in pediatric malignancies;Mossé;Clin Cancer Res,2016

2. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma;Morris;Science,1994

3. Oncogenic mutations of ALK kinase in neuroblastoma;Chen;Nature,2008

4. Emerging importance of ALK in neuroblastoma;Azarova;Semin Cancer Biol,2011

5. ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor;Coffin;Mod Pathol,2001

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Complete morphologic response to gilteritinib in ALK-rearranged acute myeloid leukemia;npj Precision Oncology;2024-09-10

2. Current Knowledge and Perspectives of Immunotherapies for Neuroblastoma;Cancers;2024-08-17

3. mRNA Expression Level of ALK in Neuroblastoma Is Associated with Histological Subtype, ALK Mutations and ALK Immunohistochemical Protein Expression;Journal of Molecular Pathology;2024-08-01

4. Evolution of the Innovative Therapies for Children With Cancer Consortium Trial Portfolio for Drug Development for Children With Cancer;Journal of Clinical Oncology;2024-07-20

5. Crizotinib therapy for congenital embryonal rhabdomyosarcoma associated with an ATIC–ALK gene fusion;Pediatric Blood & Cancer;2024-06-17